MONOVISC is a single high dose viscosupplement injection for the treatment of OA in the knee joint

  • Highest concentration HA creates a high viscosity environment to replicate healthy joint function
  • Optimal high-molecular-weight results in greater pain reduction and longer duration of effect
  • Lightly cross-linked HA leads to longer residence time in joint and better viscoelasticity of synovial fluid
  • Ultra pure non-avian HMW HA produced via bacterial fermentation – no adverse events reported and only a 2.5% rate of mild injection site reactions
  • MONOVISC delivers a 65% improvement in WOMAC pain at week 26 relative to baseline (p =0.0352)
  • High concentrate Hyaluronate Acid
  • MONOVISC delivers an 85% responder rate in the OMERACT-OARSI Responder Index through 26 weeks
  • MONOVISC patients experienced a clinically meaningful reduction in OA knee pain within two weeks of their injection

The synthesis of hyaluronic acid...

The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment

MONOVISC® brochure

Product Enquiry